AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
IDEAYA Biosciences Secures Clearance for IDE034
ByAinvest
Monday, Dec 1, 2025 11:32 am ET1min read
Ideaya Biosciences has announced clearance for IDE034, a precision medicine oncology company developing targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (IDE196), IDE397, IDE161, and GSK101. IDE196 is a PKC inhibitor being evaluated as a synthetic lethal combination therapy, while IDE397 is a MAT2A inhibitor for solid tumors with MTAP deletions. IDE161 is a PARG inhibitor for tumors with defined biomarkers based on genetic mutations and/or molecular signatures.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet